selected scholarly activity
-
academic article
- An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes. Thrombosis Research. 136:1053-1054. 2015
- Appropriate Assessment of the Functional Consequences of Platelet Cyclooxygenase-1 Inhibition by Aspirin in vivo. Thrombosis Research. 133:697-698. 2014
- Effective, selective and specific inhibition of COX-1 may overcome the “aspirin paradox”. Thrombosis Research. 132:1-2. 2013
- The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studiesin vitro. Haemophilia. 18:917-925. 2012
- Management of bleeding disorders: basic science. Haemophilia. 18:8-14. 2012
- Understanding FVIII/VWF complex - report from a symposium of XXIX WFH meeting 2010. Haemophilia. 18:469-475. 2012
- A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Thrombosis and Haemostasis. 107:201-214. 2012
- Immune Responses Associated With Perioperative Exposure and Reexposure to Topical Bovine Thrombin Do Not Impair Hemostasis. Clinical and Applied Thrombosis/Hemostasis. 17:620-632. 2011
- Safety and Efficacy of Thrombin-JMI: A Multidisciplinary Expert Group Consensus. Clinical and Applied Thrombosis/Hemostasis. 17:39-45. 2011
- The United States Food and Drugs Administration Approves a Generic Enoxaparin. Clinical and Applied Thrombosis/Hemostasis. 17:5-8. 2011
- Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism. Thrombosis Research. 124:281-287. 2009
- Recommendations on biosimilar low-molecular-weight heparins. Journal of Thrombosis and Haemostasis. 7:1222-1225. 2009
- A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clinical Therapeutics. 31:679-691. 2009
- Early Intraplatelet Signaling Enhances the Release of Human Platelet PAR-1 and -4 Amino-Terminal Peptides in Response to Thrombin†. Biochemistry. 48:1562-1572. 2009
- Coordinate Activation of Human Platelet Protease-activated Receptor-1 and -4 in Response to Subnanomolar α-Thrombin. Journal of Biological Chemistry. 283:26886-26893. 2008
- Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate. British Journal of Haematology. 140:589-592. 2008
- Current use of biologicals in thrombosis and haemostasis. Thrombosis and Haemostasis. 99:805-806. 2008
- Differences in the safety profiles of two low-molecular-weight heparins. Thrombosis and Haemostasis. 99:989-990. 2008
- Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thrombosis and Haemostasis. 99:874-882. 2008
- Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases. Thrombosis Research. 123:5-7. 2008
- Plasma-derived biological medicines used to promote haemostasis. Thrombosis and Haemostasis. 99:851-862. 2008
- Propagating factor IX-producing hepatocytes for haemophilia B therapy. Thrombosis and Haemostasis. 99:799-800. 2008
- Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. Journal of Gene Medicine. 9:1002-1010. 2007
- Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. Blood Coagulation and Fibrinolysis. 18:219-225. 2007
- Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Journal of Gene Medicine. 8:362-369. 2006
- Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thrombosis and Haemostasis. 96:568-577. 2006
- Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 70:110-118. 2005
- Statins and Thrombin. Current Drug Targets - Cardiovascular and Haematological Disorders. 5:115-120. 2005
- Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and Haemostasis. 94:958-964. 2005
- Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia. 10:459-469. 2004
- Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfusion and Apheresis Science. 28:265-268. 2003
- Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). American Journal of Hematology. 69:192-199. 2002
- Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. Journal of Gene Medicine. 4:215-223. 2002
- The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.. Biochemistry (Moscow) Biokhimiia (Moscow, Russia). 67:47-55. 2002
- Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia. 7:207-214. 2001
- Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII. Journal of Biological Chemistry. 275:34894-34900. 2000
- HUMAN PLATELET THROMBIN RECEPTORS. Hematology/Oncology Clinics of North America. 14:1185-1198. 2000
- Delivery of recombinant product from subcutaneous implants of encapsulated recombinant cells in canines. Journal of Laboratory and Clinical Medicine Translational Research. 135:484-492. 2000
- Therapeutic approaches for haemophilia. Expert Opinion on Therapeutic Patents. 10:929-938. 2000
- STATIN DRUGS AND DIETARY ISOPRENOIDS AS ANTITHROMBOTIC AGENTS. Hematology/Oncology Clinics of North America. 14:483-490. 2000
- State-of-the-Art-Review : Statins Induce Hypothrombotic States?. Clinical and Applied Thrombosis/Hemostasis. 6:18-21. 2000
- The Cleaved Peptide of PAR1 Results in a Redistribution of the Platelet Surface GPIb-IX-V Complex to the Surface-Connected Canalicular System. Thrombosis and Haemostasis. 84:897-903. 2000
- Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable Microcapsules. Human Gene Therapy. 10:1281-1288. 1999
- A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation. Biochemical Journal. 336:283-285. 1998
- PRE‐OPERATIVE FACTOR Xa–TFPI AND POST‐OPERATIVE VENOUS THROMBOSIS. British Journal of Haematology. 101:793-792. 1998
- Pharmacological Actions of Sulodexide. Seminars in Thrombosis and Hemostasis. 24:127-138. 1998
- Thrombin and Antithrombotics. Seminars in Thrombosis and Hemostasis. 24:87-91. 1998
- Platelet activation induced by porcine factor VIII (HYATE:C). American Journal of Hematology. 57:200-205. 1998
- Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain.. Blood. 91:142-148. 1998
- Binding of Thrombin to the G-protein-linked Receptor, and Not to Glycoprotein Ib, Precedes Thrombin-mediated Platelet Activation. Journal of Biological Chemistry. 272:1997-2004. 1997
- Probable regulation of factor VIIa–tissue factor and prothrombinase by factor Xa–TFPI and TFPI in vivo. British Journal of Haematology. 95:738-746. 1996
- Age-related changes in factor VII proteolysisin vivo. British Journal of Haematology. 94:407-412. 1996
- Control Mechanisms in Thrombin Generation. Seminars in Thrombosis and Hemostasis. 22:303-308. 1996
- Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B.. Blood. 87:5095-5103. 1996
- Plasmin accelerates platelet‐dependent prothrombinase formation without activating the platelets. British Journal of Haematology. 92:458-465. 1996
- Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation. 92:2819-2824. 1995
- Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo. British Journal of Haematology. 90:669-680. 1995
- Anticoagulant Actions of Tissue Factor Pathway Inhibitor on Tissue-Factor-Dependent Plasma Coagulation. Seminars in Thrombosis and Hemostasis. 21:240-244. 1995
- Inhibition of Thrombin by Antithrombin III and Heparin Cofactor II In Vivo. Thrombosis and Haemostasis. 74:405-412. 1995
- Thrombin binding to platelets and their activation in plasma. British Journal of Haematology. 88:592-600. 1994
- Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. Seminars in Thrombosis and Hemostasis. 20:324-327. 1994
- Is Heparin the Ideal Anticoagulant for Cardiopulmonary Bypass? Dermatan Sulphate May Be an Alternate Choice. Thrombosis and Haemostasis. 72:468-473. 1994
- Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma. Thrombosis and Haemostasis. 72:862-868. 1994
- Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II. Thrombosis Research. 74:463-475. 1994
- The hypercoagulable state in cancer patients. Blood Coagulation and Fibrinolysis. 5:S19-23. 1994
- Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. British Journal of Haematology. 85:745-750. 1993
- Understanding Thrombin and Hemostasis. Hematology/Oncology Clinics of North America. 7:1107-1119. 1993
- Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant?. Thrombosis and Haemostasis. 70:259-262. 1993
- Expression of Human Factor IX by Microencapsulated Recombinant Fibroblasts. Human Gene Therapy. 4:291-301. 1993
- The direct binding of human factor VII in plasma to recombinant human tissue factor. Thrombosis Research. 70:307-316. 1993
- An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. Thrombosis and Haemostasis. 69:231-235. 1993
- The effects of heparin and dermatan sulphate on t-PA-induced thrombolysis and blood loss in rabbits. Fibrinolysis. 7:75-81. 1993
- Mechanisms for the Anticoagulant Effects of Synthetic Antithrombins. Advances in Experimental Medicine and Biology. 340:213-226. 1993
- Modulation of intrinsic prothrombin activation by fibrinogen and fibrin I.. Journal of Laboratory and Clinical Medicine Translational Research. 121:64-70. 1993
- Prophylactic doses of enoxaparin and heparin inhibit prothrombin activation.. Seminars in Thrombosis and Hemostasis. 19 Suppl 1:29-30. 1993
- Bioregulatory roles for fibrin(ogen) on blood coagulation. Medical Hypotheses. 39:152-155. 1992
- Prevention of Thrombus Growth by Antithrombin III-Dependent and Two Direct Thrombin Inhibitors in Rabbits: Implications for Antithrombotic Therapy. Thrombosis and Haemostasis. 68:424-427. 1992
- Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent. British Journal of Haematology. 82:400-405. 1992
- The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. British Journal of Haematology. 82:391-399. 1992
- A novel congenital haemostatic defect: combined factor VII and factor XI deficiency.. Blood Coagulation and Fibrinolysis. 3:357-360. 1992
- Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients. British Journal of Haematology. 81:539-544. 1992
- Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors ofα-thrombin. Biochemical Journal. 283:893-897. 1992
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. Thrombosis and Haemostasis. 67:542-544. 1992
- Thrombin Inhibition Is Impaired in Plasma of Sick Neonates. Pediatric Research. 31:391-395. 1992
- The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor. FEBS Letters. 298:206-210. 1992
- Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849). Pathophysiology of Haemostasis and Thrombosis Haemostasis. 22:66-72. 1992
- Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. FEBS Journal European Journal of Biochemistry. 203:121-125. 1992
- Prophylactically Effective Doses of Enoxaparin and Heparin Inhibit Prothrombin Activation. Advances in Experimental Medicine and Biology. 313:231-236. 1992
- Thrombin Regulation in Mother and Fetus During Pregnancy. Seminars in Thrombosis and Hemostasis. 18:81-90. 1992
- Heparin sensitivity and resistance in the neonate: An explanation. Thrombosis Research. 63:85-98. 1991
- Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.. Blood. 77:2185-2189. 1991
- Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.. Journal of Laboratory and Clinical Medicine Translational Research. 117:359-364. 1991
- Thrombin structure and function. Blood Coagulation and Fibrinolysis. 2:69-76. 1991
- Modulation of the Enzymatic Activity of α-Thrombin by Polyanions: Consequences on Intrinsic Activation of Factor V and Factor VIII. Pathophysiology of Haemostasis and Thrombosis Haemostasis. 21:240-247. 1991
- Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin. Pathophysiology of Haemostasis and Thrombosis Haemostasis. 21:27-31. 1991
- Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and d-Phe-Pro-Arg-Ch2Cl. Biochemical Journal. 272:399-406. 1990
- Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. FEBS Journal European Journal of Biochemistry. 193:485-493. 1990
- 2 Mechanisms of action of low molecular weight heparins and heparinoids. Best Practice and Research in Clinical Haematology Bailliere's Clinical Haematology. 3:505-529. 1990
- The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice. Thrombosis and Haemostasis. 63:413-416. 1990
- A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. British Journal of Haematology. 74:471-479. 1990
- Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate. Thrombosis and Haemostasis. 63:271-274. 1990
- INVITRO AND EXVIVO ACTIVITIES OF CY216 - COMPARISON WITH OTHER LOW-MOLECULAR-WEIGHT HEPARINS. Pathophysiology of Haemostasis and Thrombosis Haemostasis. 20:180-192. 1990
- In vitro and ex vivo Activities of CY216: Comparison with Other Low Molecular Weight Heparins. Pathophysiology of Haemostasis and Thrombosis Haemostasis. 20:180-192. 1990
- Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma.. Thrombosis and Haemostasis. 62:1074-1077. 1989
- The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thrombosis Research. 56:529-539. 1989
- Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo. Annals of the New York Academy of Sciences. 556:304-312. 1989
- Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbits. Annals of the New York Academy of Sciences. 556:245-254. 1989
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfate. Annals of the New York Academy of Sciences. 556:123-131. 1989
- Anticoagulant Effects of Heparin in Neonatal Plasma'. Pediatric Research. 25:405-408. 1989
- Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.. Thrombosis and Haemostasis. 61:7-9. 1989
- Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. British Journal of Haematology. 71:265-269. 1989
- Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochemical Journal. 257:143-150. 1989
- Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thrombosis Research. 52:517-527. 1988
- Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.. Blood. 72:1518-1523. 1988
- An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition. Thrombosis and Haemostasis. 60:193-198. 1988
- Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits. Thrombosis and Haemostasis. 60:188-192. 1988
- Mechanisms for the anticoagulant effect of heparin and related polysaccharides.. Nouvelle Revue Francaise d'Hematologie. 30:155-160. 1988
- Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties. Seminars in Thrombosis and Hemostasis. 14:9-17. 1988
- THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC AND FIBRINOLYTIC DRUGS - A MECHANIC POINT OF VIEW - PREFACE. Seminars in Thrombosis and Hemostasis. 14:U1-U1. 1988
- Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochemical Journal. 248:889-896. 1987
- Evolution of Thrombosis. Annals of the New York Academy of Sciences. 516:586-604. 1987
- Catalysis of Thrombin Inhibition Provides an Index for Estimating the Antithrombotic Potential of Glycosaminoglycans in Rabbits. Thrombosis and Haemostasis. 57:286-293. 1987
- The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochemical Journal. 243:579-588. 1987
- Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma. Vox Sanguinis. 52:254-256. 1987
- THE BLOOD-TRANSFUSION EFFECT - CHARACTERIZATION OF T-CELL ALLOANTIGEN-SPECIFIC RECEPTORS BY SERA FROM TRANSFUSED MICE. Transplantation Proceedings. 19:1429-1431. 1987
- The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice.. Transplantation Proceedings. 19:1429-1431. 1987
- Factor VIII concentrate for hemophilia: comparison of two heat-treated products.. CMAJ. 136:150-152. 1987
- INDUCTION OF ANTIIDIOTYPIC ANTIBODIES BY BLOOD TRANSFUSIONS. Transplantation. 42:632-635. 1986
- Mechanisms for Inhibition of the Generation of Thrombin Activity by Sulfated Polysaccharides. Annals of the New York Academy of Sciences. 485:41-55. 1986
- Lack of Relationship Between Enhanced Bleeding Induced by Heparin and Other Sulfated Polysaccharides and Enhanced Catalysis of Thrombin Inhibition. Seminars in Thrombosis and Hemostasis. 12:324-327. 1986
- The haemorrhagic and antithrombotic effects of dermatan sulphate. British Journal of Haematology. 64:309-317. 1986
- The haemorrhagic and antithrombotic effects of dermatan sulphate.. British Journal of Haematology. 64:309-317. 1986
- Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thrombosis Research. 43:491-495. 1986
- Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?. Antimicrobial Agents and Chemotherapy. 29:1108-1109. 1986
- The immunodepletion of factor VII from human plasma using a monoclonal antibody. British Journal of Haematology. 61:467-475. 1985
- Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth. Thrombosis Research. 40:81-89. 1985
- Approaches to the measurement of the response to Factor VIII concentrate infusion. Thrombosis Research. 39:429-437. 1985
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. British Journal of Haematology. 60:695-704. 1985
- Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate. Seminars in Thrombosis and Hemostasis. 11:133-137. 1985
- Use of Segments for the Quality Control of the Factor VIII: Coagulant Activity of Fresh Frozen Plasma. Vox Sanguinis. 48:213-216. 1985
- Rationale Behind the Development of Low Molecular Weight Heparin Derivatives. Seminars in Thrombosis and Hemostasis. 11:13-16. 1985
- The isolation of prothrombin, factor IX and factor X from human factor IX concentrates. Thrombosis Research. 36:537-547. 1984
- Assessment of Methods for Cytomegalovirus Antibody Testing of Blood Donations. Vox Sanguinis. 47:343-347. 1984
- Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Canadian Journal of Biochemistry and Cell Biology. 62:975-983. 1984
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.. Blood. 64:742-747. 1984
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. British Journal of Haematology. 57:229-238. 1984
- HEPARAN-SULFATE AND DERMATAN SULFATE INHIBIT THE GENERATION OF THROMBIN ACTIVITY IN PLASMA BY COMPLEMENTARY PATHWAYS. Blood. 64:727-747. 1984
- North American study of factor VIII concentrate potency.. Scandinavian journal of haematology. Supplementum. 40:149-160. 1984
- Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thrombosis Research. 28:487-497. 1982
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. Thrombosis Research. 23:331-345. 1981
- The factor VIII-independent activation of factor X by factors IXa and VII in plasma. Thrombosis Research. 21:23-33. 1981
- The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thrombosis Research. 20:391-403. 1980
- Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thrombosis Research. 20:77-83. 1980
- Radloimmunoassay of intestinal goblet cell mucin. Analytical Biochemistry. 83:657-665. 1977
-
conference paper
- The fraction of recombinant factor VIII unable to bind VWF is inactive. Haemophilia. 562-562. 2011
- Loss of ATP secretion contributes to the decreased responses of stored platelets to thrombin. Transfusion. 166A-166A. 2008
- Argatroban inhibits human factor Xa at therapeutic drug levels: An explanation for its prolongation of the INR.. Blood. 511A-511A. 2004
- Either reducing or increasing the molecular volume of recombinant factor IX accelerates its overall clearance in a mouse model of Hemophilia B. Transfusion. 64A-65A. 2004
- Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology. 565-573. 2004
- Partial correction of the hemophilic phenotype in mice implanted with encapsulated human primary myoblasts secreting FIX. Molecular Therapy. S64-S64. 2004
- Cleavage of protease-activated receptor 1(PAR-1) by a platelet protease and thrombin: Modulation by soybean trypsin inhibitor, glycoprotein IB(GPIB), and anti-protease-activated receptor antibodies.. Transfusion. 104S-104S. 2000
- Therapeutic levels of human factor VIII in mice implanted with encapsulated recombinant myoblasts: Potential for gene therapy of hemophilia A. Transfusion. 1S-1S. 2000
- Biology of the hypercoagulable state following major trauma.. Blood. 240A-241A. 1999
- A trypsin-like platelet protease must generate PAR-1 residues 1-41 and PAR-1 tethered ligand to optimize propagation of platelet activation. Thrombosis and Haemostasis. 821-821. 1999
- Biology of the hypercoagulable state following major trauma. Thrombosis and Haemostasis. 405-405. 1999
- Calcium dependency of conformational changes in the EGF-1 region upon activation, but not active site inhibition, of human FVII. Thrombosis and Haemostasis. 466-466. 1999
- Cleavage of protease-activated receptor-1 (PAR-1) and platelet activation by alpha- and gamma-thrombins. Thrombosis and Haemostasis. 817-817. 1999
- Glycoprotein Ib (GPIb) modulates protein tyrosine phosphorylation to enhance platelet protease-activated receptor-1 (PAR-1) cleavage by a-thrombin. Thrombosis and Haemostasis. 817-817. 1999
- Statins, thrombin suppression, and hypothrombotic states. Thrombosis and Haemostasis. 191-191. 1999
- Sustained delivery of therapeutic levels of human factor IX in nude hemophilic mice implanted with encapsulated mouse myoblasts secreting human factor IX. Thrombosis and Haemostasis. 279-279. 1999
- Unactivated platelets provide factor IX necessary to optimize propagation of tissue factor (TF)-dependent coagulation. Thrombosis and Haemostasis. 713-713. 1999
- Both activation and active site occupation of human factor VII alter conformation of the first EGF-life domain.. Blood. 41A-41A. 1998
- Misfolding of the first epidermal growth factor domain results in decreased cellular secretion of factor VII. Thrombosis and Haemostasis. P1651-P1651. 1997
- Relationship between cleavage of the 7-transmembrane receptor on platelets and platelet activation by alpha-thrombin. Thrombosis and Haemostasis. PS253-PS253. 1997
- Catalytically equivalent doses of heparin and dermatan sulphate inhibit platelet-dependent prothrombinase formation to the same extent in plasma.. Blood. 3507-3507. 1995
- Thrombin-mediated platelet activation is due to the cleavage of the cloned thrombin receptor and independent of platelet glycoprotein Ib.. Blood. 2180-2180. 1995
- FACTOR-XA-ANTITHROMBIN-III ENDOGENOUS TO PLASMA - RELATIONSHIP TO PROTHROMBIN ACTIVATION IN-VIVO. Thrombosis and Haemostasis. 1250-1250. 1995
- INHIBITION OF THROMBIN-INDUCED PLATELET ACTIVATION BY SYNTHETIC ANTI-THROMBINS IN PLASMA. Thrombosis and Haemostasis. 1451-1451. 1995
- SITES OF TISSUE FACTOR-DEPENDENT PLASMA COAGULATION SUBJECT TO INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR. Thrombosis and Haemostasis. 943-943. 1995
- PLATELETS ARE THE PRIMARY SOURCE OF FACTOR VA FOR PROTHROMBINASE FORMATION IN PLATELET-RICH PLASMA. Blood. A191-A191. 1994
- THROMBIN-MEDIATED EVENTS IMPLICATED IN POSTTHROMBOTIC RECOVERY. ANGIOGENESIS. 253-263. 1994
- CONSEQUENCES OF THE INTERACTIONS OF FIBRINOGEN, FIBRIN-I AND GLYCOSAMINOGLYCANS ON PROTHROMBIN ACTIVATION IN HUMAN PLASMA. Thrombosis and Haemostasis. 1260-1260. 1993
- CONTRAST-MEDIA INDUCES THROMBIN GENERATION DURING PTCA. Thrombosis and Haemostasis. 1014-1014. 1993
- DERMATAN SULFATE PREVENTS PROTHROMBIN CONSUMPTION DURING CARDIOPULMONARY BYPASS MORE EFFECTIVELY THAN HEPARIN. Thrombosis and Haemostasis. 890-890. 1993
- EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA AND VESSEL WALL OCCLUSION. Thrombosis and Haemostasis. 807-807. 1993
- EFFECTS OF SELECTIVE THROMBIN OR FACTOR-XA INHIBITORS ON THE ASSEMBLY OF PLATELET-BOUND PROTHROMBINASE IN PLASMA. Thrombosis and Haemostasis. 812-812. 1993
- EVIDENCE FOR HEPARIN COFACTOR-II (HCII) AS A PHYSIOLOGICAL INHIBITOR OF THROMBIN. Thrombosis and Haemostasis. 899-899. 1993
- EVIDENCE FOR PROTHROMBIN ACTIVATION AND IMPAIRED THROMBIN INHIBITION IN CANCER-PATIENTS. Thrombosis and Haemostasis. 573-573. 1993
- FACTOR-VII HAMILTON - A NOVEL TYPE-2 MUTATION LOCATED AT RESIDUE-57 IN THE 1ST EGF DOMAIN OF HUMAN FACTOR-VII. Thrombosis and Haemostasis. 1291-1291. 1993
- INACTIVATION OF FACTOR-VIIIA BY FACTOR-XA. Thrombosis and Haemostasis. 1087-1087. 1993
- INACTIVATION OF FACTOR-VIIIA BY THROMBIN. Thrombosis and Haemostasis. 1087-1087. 1993
- SIMULTANEOUS INHIBITION OF THROMBIN BY ATIII AND HCII AND PREVENTION OF THROMBUS FORMATION AND GROWTH - RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE. Thrombosis and Haemostasis. 667-667. 1993
- THROMBIN GENERATION DURING CARDIAC-SURGERY - IS HEPARIN THE IDEAL ANTICOAGULANT. Thrombosis and Haemostasis. 654-654. 1993
- EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA. Thrombosis Research. S72-S72. 1993
- MECHANISMS FOR THE ANTITHROMBOTIC EFFECTS OF GLYCOSAMINOGLYCANS. Thrombosis Research. S161-S161. 1993
- RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE ON PREVENTION OF THROMBUS FORMATION AND GROWTH. Thrombosis Research. S161-S161. 1993
- ANTITHROMBIN-III INDEPENDENT THROMBIN INHIBITORS PREVENT THROMBUS GROWTH MORE EFFECTIVELY THAN HEPARIN - IMPLICATIONS FOR ANTITHROMBOTIC THERAPY. Thrombosis and Haemostasis. 829-829. 1991
- DERMATAN SULFATE ANTICOAGULATION DURING CARDIOPULMONARY BYPASS REDUCES BLEEDING AND ELIMINATES THE NEED OF PROTAMINE NEUTRALIZATION. Thrombosis and Haemostasis. 863-863. 1991
- DERMATAN SULFATE INCREASES TPA-INDUCED THROMBOLYSIS WITHOUT INCREASING BLEEDING IN RABBITS. Thrombosis and Haemostasis. 787-787. 1991
- FIBRIN MODERATES THROMBIN INHIBITION BY ANTITHROMBIN III/HEPARIN BUT NOT THROMBIN INHIBITION BY HEPARIN-COFACTOR II/DERMATAN SULFATE. Thrombosis and Haemostasis. 759-759. 1991
- INHIBITION OF THE AMPLIFICATION REACTIONS OF COAGULATION BY SITE-SPECIFIC INHIBITORS OF ALPHA-THROMBIN. Thrombosis and Haemostasis. 650-650. 1991
- INHIBITION OF THROMBUS GROWTH IS ACHIEVED MORE EFFECTIVELY BY CATALYZING THROMBIN INHIBITION BY DERMATAN SULFATE HEPARIN COFACTOR-II THAN BY HEPARIN ANTITHROMBIN-III. Thrombosis and Haemostasis. 785-785. 1991
- THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPARIN MODERATES FACTOR-VII AND PROTHROMBIN CONSUMPTION ASSOCIATED WITH ELECTIVE KNEE SURGERY. Thrombosis and Haemostasis. 1298-1298. 1991
- COAGULATION AND FIBRINOLYSIS ARE ENHANCED IN SICKLE-CELL DISEASE. FASEB Journal. A523-A523. 1991
- THE EFFECT OF GLYCOSAMINOGLYCANS ON VESSEL WALL PERMEABILITY IN RABBITS. ADVANCES IN VASCULAR PATHOLOGY 1990, VOL 3. 201-207. 1990
- ACTIVATION OF PLASMA FACTOR-V BY THROMBIN AND FACTOR-XA - INHIBITION BY HIRUDIN AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ANTITHROMBIN-III. Thrombosis and Haemostasis. 33-33. 1989
- ALPHA-2-MACROGLOBULIN MAY PROVIDE PROTECTION FROM THROMBOEMBOLIC EVENTS IN ANTITHROMBIN-III DEFICIENT CHILDREN. Thrombosis and Haemostasis. 382-382. 1989
- HEPARIN, DERMATAN SULFATE AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ATIII INHIBIT COAGULATION BY DELAYING PROTHROMBINASE FORMATION. Thrombosis and Haemostasis. 516-516. 1989
- HEPARIN SENSITIVITY AND RESISTANCE IN THE NEWBORN - AN EXPLANATION. Pediatric Research. A274-A274. 1989
- EFFECTS OF DERMATAN SULFATE AND HEPARIN ON INHIBITION OF THROMBUS GROWTH-INVIVO. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 304-312. 1989
- EFFECTS OF UNFRACTIONATED HEPARIN, DERMATAN SULFATE AND LOW-MOLECULAR WEIGHT HEPARIN ON VESSEL WALL PERMEABILITY IN RABBITS. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 245-254. 1989
- PLASMA ANTICOAGULANT MECHANISMS OF HEPARIN, HEPARAN-SULFATE, AND DERMATAN SULFATE. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 123-131. 1989
- THROMBIN GENERATION IN NEWBORN PLASMA IS DEPENDENT ON PROTHROMBIN CONCENTRATION. Arteriosclerosis. A664-A664. 1988
- ALPHA-2-MACROGLOBULIN IS A MORE IMPORTANT INHIBITOR OF THROMBIN IN INFANT PLASMA THAN IN ADULT PLASMA. Thrombosis and Haemostasis. 400-400. 1987
- HEPARIN IS NOT AN EFFICIENT INHIBITOR OF THE FACTOR XA-DEPENDENT ACTIVATION OF FACTOR-V AND FACTOR-VIII. Thrombosis and Haemostasis. 36-36. 1987
- INCREASED SULFATION IMPROVES THE ABILITY OF VESSEL WALL GLYCOSAMINOGLYCANS TO REGULATE THROMBIN ACTIVITY AND PROTHROMBIN ACTIVATION IN PLASMA. Thrombosis and Haemostasis. 126-126. 1987
- INCREASED SULFATION INCREASES THE BLEEDING SIDE-EFFECTS OF GLYCOSAMINOGLYCANS. Thrombosis and Haemostasis. 7-7. 1987
- THE EFFECTS OF SULFATED POLYSACCHARIDES ON INHIBITION OF THROMBOSIS INDUCED BY DIFFERENT STIMULI. Thrombosis and Haemostasis. 7-7. 1987
- DDAVP REDUCES THE PLATELET DEFECT ASSOCIATED WITH HEPARIN. Circulation. 95-95. 1986
- DETECTION OF PLASMA INHIBITORS OF THROMBIN. Seminars in Thrombosis and Hemostasis. 341-342. 1986
- INHIBITION OF THROMBIN GENERATION INVITRO REQUIRES LESS HEPARIN IN THE NEWBORN THAN IN THE ADULT. Clinical and Investigative Medicine. A78-A78. 1986
- A DERMATAN SULFATE-LIKE ANTICOAGULANT IN THE FETAL LAMB AFTER ADMINISTRATION OF PK-10169 TO THE EWE. Thrombosis and Haemostasis. 32-32. 1985
- CONTRIBUTIONS OF ANTI-FACTOR-XA AND ANTI-THROMBIN ACTIVITIES OF GLYCOSAMINOGLYCANS (GAGS) TO THEIR ANTICOAGULANT AND ANTITHROMBOTIC PROPERTIES. Thrombosis and Haemostasis. 97-97. 1985
- EVIDENCE THAT INTACT HUMAN-PLATELETS PROVIDE FACTOR VII-LIKE ACTIVITY FOR THE ACTIVATION OF FACTOR-X BY THE EXTRINSIC COAGULATION PATHWAY. Thrombosis and Haemostasis. 176-176. 1985
- HEPARIN AND PENTOSAN POLYSULFATE INHIBIT THE FORMATION OF PROTHROMBINASE AND TENASE COMPLEXES IN PLASMA DEPLETED OF BOTH ANTITHROMBIN III (ATIII) AND HEPARIN COFACTOR-II (HCII). Thrombosis and Haemostasis. 95-95. 1985
- THE HEMORRHAGIC AND ANTITHROMBOTIC EFFECTS OF DERMATAN SULFATE. Thrombosis and Haemostasis. 61-61. 1985
- USE OF POLYCLONAL ANTIBODIES TO FACTOR-VII FOR THE DETECTION OF MONOCLONAL-ANTIBODIES TO FACTOR-VII. Thrombosis and Haemostasis. 263-263. 1985
- ALTERED FETAL LAMB COAGULATION AFTER ADMINISTRATION OF LOW-MOLECULAR WEIGHT HEPARIN TO THE EWE. Circulation. 362-362. 1984
- HEPARIN SULFATE AND DERMATAN SULFATE INHIBIT THROMBIN GENERATION IN PLASMA. Thrombosis and Haemostasis. 226-226. 1983